Methods for treating mucopolysaccharidosis
US-2024374534-A1 · Nov 14, 2024 · US
Calebin A for hepatic steatosis
US9737502B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9737502-B2 |
| Application number | US-201514690438-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 19, 2015 |
| Priority date | Jan 10, 2011 |
| Publication date | Aug 22, 2017 |
| Grant date | Aug 22, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention discloses the potential of Calebin A in attenuating high fat diet (HFD) induced hepatic steatosis in mammals.
First claim
Opening claim text (preview).
We claim: 1. A method of restoring adipocyte size in the fat tissue of obese mammals, said method comprising step of bringing into contact (a) enlarged mammalian adipocytes wherein enlargement resulting from a high fat diet regime, and (b) Calebin-A by orally administering effective concentrations of Calebin-A to said mammals, to achieve the effect of restoration of normal adipocyte size in fat tissue. 2. A method of treating high fat diet (HFD) induced hepatic steatosis in mammals, said method comprising step of bringing into contact HFD affected hepatic cells marked by inflammatory infiltration, hepatocellular ballooning degeneration and high triglyceride levels with Calebin-A by orally administering to said mammals effective concentrations of Calebin-A to bring about the effect of attenuation of hepatic steatosis in a dose dependant manner.
Assignees
Inventors
Classifications
from plants · CPC title
- A61K31/235Primary
having an aromatic ring attached to a carboxyl group · CPC title
Adipocytes; Adipose tissue · CPC title
of acids having aromatic rings, e.g. benactizyne, clofibrate · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9737502B2 cover?
- The present invention discloses the potential of Calebin A in attenuating high fat diet (HFD) induced hepatic steatosis in mammals.
- Who is the assignee on this patent?
- Nagabhushanam Kalyanam, Majeed Anju, Majeed Muhammed, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/235. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 22 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).